Last Price$395.5(0.3%)
Market Cap$90.7B
P/EBITDA LTM
7.9x
5Y avg
10.5x
Medical - Healthcare Plans industry
median
6.0x
Stock quality & Intrinsic value
7/10
1.5% undervalued
Elevance Health Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 14.2x | 9.8x | 8.7x | 5.3x | 6.4x | 2.5x | 4.4x | 4.2x | 5.3x | 10.0x | 7.9x | 7.0x | 10.4x | 11.5x | 11.6x | 9.1x | 12.3x | 11.7x | 10.3x | 7.9x |
Overvalued or undervalued?
Check the intrinsic value for ELV
and see if it's the right time to invest.
Elevance Health Inc. (ELV) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Elevance Health Inc.ELV
2.1x
3.2%
(0.0%)
3.4%
Median Peer Set
7.7x
8.9%
(18.9%)
1.2%
Oscar Health, Inc.OSCR
41.7x
56.5%
N/A
0.3%
UnitedHealth Group IncorporatedUNH
18.3x
8.9%
(35.7%)
3.6%
Humana Inc.HUM
9.2x
10.7%
(50.1%)
1.0%
Molina Healthcare, Inc.MOH
9.2x
19.3%
9.2%
2.9%
Cigna CorporationCI
7.7x
8.4%
(18.9%)
2.6%
CVS Health CorporationCVS
6.0x
4.2%
(43.6%)
1.2%
Centene CorporationCNC
5.3x
5.9%
27.4%
2.0%
Alignment Healthcare, Inc.ALHC
(40.1x)
27.2%
(4.8%)
(8.1%)
Clover Health Investments, Corp.CLOV
(42.6x)
(41.5%)
(31.3%)
(10.5%)
ELV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 45,150.8 116.9% | 57,009.2 26.3% | 61,394.0 7.7% | 62,459.0 1.7% | 61,644.3 (1.3%) | 58,841.2 (4.5%) | 60,804.0 3.3% | 61,535.0 1.2% | 71,122.4 15.6% | 73,923.1 3.9% | 79,239.9 7.2% | 84,978.4 7.2% | 90,039.4 6.0% | 92,105.0 2.3% | 104,213.0 13.1% | 121,867.0 16.9% | 138,639.0 13.8% | 156,595.0 13.0% | 171,340.0 9.4% | 176,810.0 3.2% |
| Cost of Goods Sold (COGS) | 33,507.9 | 42,520.0 | 46,436.3 | 48,210.9 | 46,990.1 | 44,926.9 | 47,647.5 | 48,213.6 | 56,237.1 | 56,854.9 | 61,116.9 | 66,834.4 | 72,236.2 | 71,895.0 | 81,786.0 | 88,045.0 | 102,645.0 | 116,642.0 | 124,330.0 | 19,750.0 |
% margin | 11,642.9 25.8% | 14,489.2 25.4% | 14,957.7 24.4% | 14,248.1 22.8% | 14,654.2 23.8% | 13,914.3 23.6% | 13,156.5 21.6% | 13,321.4 21.6% | 14,885.3 20.9% | 17,068.2 23.1% | 18,123.0 22.9% | 18,144.0 21.4% | 17,803.2 19.8% | 20,210.0 21.9% | 22,427.0 21.5% | 33,822.0 27.8% | 35,994.0 26.0% | 39,953.0 25.5% | 47,010.0 27.4% | 157,060.0 88.8% |
| Operating Expenses | 7,511.1 | 9,126.2 | 9,003.0 | 9,287.5 | 9,711.6 | 9,081.1 | 8,675.0 | 8,913.5 | 10,198.2 | 11,969.3 | 12,764.9 | 12,724.9 | 12,818.0 | 14,373.0 | 15,694.0 | 26,111.0 | 27,048.0 | 31,502.0 | 38,265.0 | 20,025.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 4,131.8 9.2% | 5,363.0 9.4% | 5,954.7 9.7% | 4,960.6 7.9% | 4,942.6 8.0% | 4,833.2 8.2% | 4,481.5 7.4% | 4,407.9 7.2% | 4,687.1 6.6% | 5,098.9 6.9% | 5,358.1 6.8% | 5,419.1 6.4% | 4,985.2 5.5% | 5,837.0 6.3% | 6,733.0 6.5% | 7,711.0 6.3% | 8,946.0 6.5% | 8,451.0 5.4% | 8,745.0 5.1% | 137,236.0 77.6% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 226.7 | 392.4 | 437.1 | 488.9 | 447.6 | 418.9 | 430.3 | 511.8 | 602.7 | 600.7 | 653.0 | 723.0 | 739.0 | 753.0 | 746.0 | 784.0 | 798.0 | 851.0 | 1,030.0 | 1,185.0 |
| Pre-tax Income | 3,890.3 | 4,914.4 | 5,257.9 | 3,122.4 | 7,403.0 | 4,353.8 | 3,957.9 | 3,858.3 | 3,840.2 | 4,368.1 | 4,631.0 | 4,555.4 | 3,963.8 | 5,068.0 | 5,985.0 | 6,238.0 | 7,925.0 | 7,600.0 | 7,715.0 | 7,904.0 |
% effective tax rate | 1,426.5 36.7% | 1,819.5 37.0% | 1,912.5 36.4% | 631.7 20.2% | 2,657.1 35.9% | 1,466.7 33.7% | 1,311.2 33.1% | 1,207.3 31.3% | 1,205.9 31.4% | 1,808.0 41.4% | 2,071.0 44.7% | 2,085.6 45.8% | 121.0 3.1% | 1,318.0 26.0% | 1,178.0 19.7% | 1,666.0 26.7% | 1,830.0 23.1% | 1,712.0 22.5% | 1,724.0 22.3% | 1,933.0 24.5% |
% margin | 2,463.8 5.5% | 3,094.9 5.4% | 3,345.4 5.4% | 2,490.7 4.0% | 4,745.9 7.7% | 2,887.1 4.9% | 2,646.7 4.4% | 2,655.5 4.3% | 2,654.2 3.7% | 2,569.7 3.5% | 2,560.0 3.2% | 2,469.8 2.9% | 3,842.8 4.3% | 3,750.0 4.1% | 4,807.0 4.6% | 4,572.0 3.8% | 6,104.0 4.4% | 5,894.0 3.8% | 5,987.0 3.5% | 5,980.0 3.4% |
| EPS | 4.03 | 4.93 | 5.64 | 4.79 | 9.96 | 7.03 | 7.35 | 8.26 | 8.89 | 9.31 | 9.73 | 9.39 | 14.70 | 14.53 | 18.81 | 18.23 | 25.04 | 24.56 | 25.69 | 25.68 |
| Diluted EPS | 3.94 | 4.82 | 5.56 | 4.76 | 9.88 | 6.94 | 7.25 | 8.18 | 8.74 | 8.95 | 9.38 | 9.21 | 14.35 | 14.19 | 18.47 | 17.98 | 24.73 | 24.28 | 25.22 | 25.68 |
% margin | 4,584.5 10.2% | 5,874.6 10.3% | 6,252.6 10.2% | 4,174.8 6.7% | 8,408.0 13.6% | 5,117.5 8.7% | 4,723.3 7.8% | 4,710.2 7.7% | 4,796.1 6.7% | 5,296.2 7.2% | 5,619.9 7.1% | 5,574.7 6.6% | 4,981.9 5.5% | 6,303.0 6.8% | 7,216.0 6.9% | 8,176.0 6.7% | 6,004.0 4.3% | 10,126.0 6.5% | 10,490.0 6.1% | 0.0 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Elevance Health Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 7.9x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Elevance Health Inc. have been 10.9x over the past three years, and 11.0x over the past five years.
2) Is Elevance Health Inc.'s P/EBITDA LTM Good?
As of today, Elevance Health Inc.'s P/EBITDA LTM is 7.9x, which is higher than industry median of 6.0x. It indicates that Elevance Health Inc.'s P/EBITDA LTM is Bad.